ReviewJournal of diabetes and metabolic disorders2025
Systematic review and meta-analysis of health outcomes following diabetes risk reduction diet (DRRD).
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, diabetes rates have reached alarming levels. Healthy dietary patterns can lower the risk of chronic diseases, and a Diabetes Risk Reduction Diet (DRRD) may have broader implications for overall health. Comprehensive research is needed to examine the association of DRRD with human health outcomes. Methods: In December 2023, a thorough literature search was conducted using multiple databases such as PubMed, Scopus, and Web of Science, along with manual inclusion of Google Scholar and Embase. The findings were analyzed using the DerSimonian, and random-effects meta-analysis was used to address study heterogeneity. Sensitivity analysis was also performed to assess the robustness of the results. Results: Finally, 26 studies, including 14 cohorts, nine case-control, and three cross-sectional studies, were systematically reviewed, with 22 included in the meta-analysis. The results revealed that a higher DRRD a higher DRRD was associated with a 23% reduced risk of cancer incidence (OR: 0.77, 95%CI: 0.67-0.88), a 36% risk reduction in cancer development (OR: 0.64, 95%CI: 0.53-0.77), a 24% reduction in mortality (OR: 0.76, 95%CI: 0.72-0.80), and a 47% reduction in the risk of Type 2 Diabetes Mellitus (OR: 0.53, 95%CI: 0.47-0.60). The sensitivity analyses show the robustness of the meta-analysis findings. Conclusion: Our findings suggest that the DRRD, designed as a diabetes-prevention diet, may have far-reaching implications for disease prevention. Its potential to prevent not only diabetes but also cancer and all-cause mortality underscores the importance of further research in this area, which could significantly impact public health strategies. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01687-5.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.